Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

15.4%

4 terminated/withdrawn out of 26 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

58%

15 trials in Phase 3/4

Results Transparency

0%

0 of 20 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
12(48.0%)
Phase 2
9(36.0%)
Phase 4
3(12.0%)
Phase 1
1(4.0%)
25Total
Phase 3(12)
Phase 2(9)
Phase 4(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials
NCT01557231Completed

Epidemiology of Osteoarthritis (OA) Pain

Role: collaborator

NCT01602757Phase 1Completed

Pharmacokinetic Study of Synera in Healthy Volunteers

Role: lead

NCT00125255Phase 3Completed

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Vascular Access Procedures in Children

Role: lead

NCT00107835Phase 3Completed

Safety Study of S-Caine Peel (Skin Numbing Cream) Before a Painful Dermatologic Procedure in Adults

Role: lead

NCT00108810Phase 2Completed

Transdermal Ketoprofen to Treat Mild to Moderate Osteoarthritis (OA) Pain of the Knee

Role: lead

NCT00110760Phase 3Completed

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Skin Filler Injection in the Face

Role: lead

NCT00110773Phase 3Completed

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Pulsed Dye Laser (PDL) Therapy in Adults

Role: lead

NCT00110253Phase 3Completed

Duration of Skin Numbing Effect Created by the S-Caine™ Peel

Role: lead

NCT00110747Phase 3Completed

S-Caine™ Peel (Skin Numbing Cream) to Treat Pain During Non-Ablative Facial Laser Resurfacing in Adults

Role: lead

NCT00126789Phase 3Terminated

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Moderate to Severe Cancer Pain

Role: lead

NCT00126763Phase 3Terminated

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Non-Malignant Pain

Role: lead

NCT00108771Phase 2Completed

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain

Role: lead

NCT00278824Phase 2Terminated

Fentanyl Transdermal Patch With CHADD™ for Breakthrough Pain in Patients With Moderate to Severe Non-Malignant Pain

Role: lead

NCT00488267Phase 3Completed

Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee

Role: lead

NCT01576770Phase 4Unknown

In Children, Does Using a Synera Patch Decrease Pain When Injecting Propofol at Anesthesia Induction?

Role: collaborator

NCT00609323Phase 2Completed

Lidocaine and Tetracaine Cream to Treat Postherpetic Neuralgia (PHN)

Role: lead

NCT00747669Phase 4Suspended

Pharmacokinetic Study of Synera™ in Neonates and Infants

Role: lead

NCT00991068Phase 2Completed

Open-Label Study Evaluating Synera® in the Treatment of Patients With Carpal Tunnel Syndrome

Role: lead

NCT00532038Phase 3Terminated

A Phase 3 Study to Evaluate the Long-Term Safety of ThermoProfen™ in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee.

Role: lead

NCT01055444Phase 2Completed

Study Evaluating Heated Lidocaine/Tetracaine Topical Patch in Treatment of Patients With Shoulder Impingement Syndrome

Role: lead